From Korea to the World: Biobytes’ Strategy for Globalizing Korean Health Innovation

As South Korea strengthens its biotech infrastructure and pushes Korean health startups toward international markets, Biobytes is pursuing a model built around scientific validation, global partnerships and Asian patient data rather than simply exporting a Korean healthcare product.

South Korea is entering a new phase in its effort to build a globally competitive biotechnology industry. The country is expanding AI-bio infrastructure, strengthening pharmaceutical partnerships and creating new pathways for domestic startups to work with global healthcare institutions. In August, the government identified advanced biotechnology as one of seven strategic growth areas and said it would establish AI-bio infrastructure by 2030 while supporting AI-driven drug discovery, autonomous laboratories and advanced gene and cell therapies.

The policy push is being matched by a growing emphasis on international collaboration. In February, South Korea’s Ministry of Health and Welfare launched the K-Biopharma Next Bridge program with global pharmaceutical companies including Roche, AbbVie, Amgen, Novo Nordisk, MSD and AstraZeneca to promote open innovation and global collaboration with Korean biopharma companies. In March, the ministry and Eli Lilly also signed an agreement tied to a planned $500 million investment in Korea’s pharmaceutical and biotechnology industry, including cooperation on global clinical trials.

The challenge now is moving from infrastructure and partnerships to globally validated products and technologies. For Korean health startups, going global is not simply a matter of selling an existing product overseas. Healthcare technologies need clinical evidence, scientific credibility, regulatory pathways and relationships with institutions that understand different patient populations and healthcare systems.

Biobytes, a South Korean digital-health startup focused on sarcopenia, is pursuing a strategy that reflects this reality. Its CEO, Jungwoo Lee, sees international conferences, pharmaceutical open innovation and clinical partnerships not as separate promotional opportunities, but as parts of a longer path toward global research and development.

“These opportunities allow us to present our work to international experts and test whether it is relevant beyond Korea,” Lee told KoreaTechToday.

That approach could offer a glimpse into how smaller Korean health companies may attempt to move from domestic innovation to participation in global healthcare R&D.

From exporting products to building global partnerships

Biobytes was established in December 2023 and is led by Lee, an orthopedic surgeon at Wonju Severance Christian Hospital with a research background spanning orthopedics, medical informatics and population-health studies. The company describes itself as a digital-health company focused on comprehensive sarcopenia management, combining AI technology with medical expertise. Its primary focus is an area of healthcare that is becoming increasingly important as populations age. Sarcopenia involves the loss of muscle mass, strength and physical function and can contribute to frailty, falls, disability and loss of independence among older adults.

Biobytes has developed AI-based approaches for assessing sarcopenia risk and is building a broader data and biomarker infrastructure around the condition. Its M-BANK initiative is designed to collect blood, tissue and medical-history data from 3,000 sarcopenia patients and control-group participants by 2027. The company says the data will support improved diagnosis and biomarker discovery for drug development, as well as AI-based precision medicine. This makes the company’s international strategy different from a conventional software export model. Rather than taking a Korean screening product and simply adapting it for overseas markets, Biobytes is trying to develop research assets that can be used in global scientific and pharmaceutical networks.

Lee made that distinction explicit.

“Personally, I do not want BioBytes to simply export a Korean screening product,” he said. “I want us to contribute high-quality Asian patient data and build global partnerships for biomarker and drug development.”

That ambition is becoming visible in the company’s 2026 activities. Biobytes has had an abstract accepted for the ASBMR 2026 Annual Meeting in Boston, selected for Daewoong Pharmaceutical’s fifth INNOBEAR Open Innovation Program and selected for a one-to-one consultation at the 2026 Mayo Clinic & DMC Partnership Day, according to Lee and the company. Taken individually, these developments are relatively small milestones for an early-stage company. Taken together, they show the different layers of internationalization Biobytes is attempting to build.

Three routes into the global healthcare ecosystem

The first route is scientific validation. The ASBMR Annual Meeting, scheduled for October 9-12 in Boston, is the world’s largest meeting focused on bone, mineral and musculoskeletal research. ASBMR says the 2026 meeting will bring together more than 2,500 clinicians and researchers from around the world. For Biobytes, presenting research in this setting provides something that an overseas sales event cannot: exposure to researchers who can evaluate the scientific relevance of its work. That distinction matters for a company working in sarcopenia. Its long-term value depends not only on whether its technology can identify patients at risk, but also on whether the underlying biomarkers, data and clinical findings can contribute to a broader understanding of muscle aging.

The second route is pharmaceutical open innovation. Biobytes’ selection for Daewoong Pharmaceutical’s INNOBEAR program places it within a Korean pharmaceutical ecosystem that is increasingly designed to work with startups and external research teams. Daewoong describes INNOBEAR as an open-innovation program for identifying promising partners and supporting the development of innovative medicines. Its wider open-collaboration model includes joint research, global expansion consulting, investment and potential business-development and commercialization partnerships.

For Biobytes, this creates a potential bridge between a disease-specific dataset and the pharmaceutical development process. The third route is international clinical validation. The 2026 Mayo Clinic & DMC Partnership Day, organized by KOTRA with Mayo Clinic and Destination Medical Center, brought Korean healthcare companies together with U.S. healthcare experts. The program explicitly focused on opportunities including U.S. market entry, clinical validation, joint research and commercialization. On the second day, 35 Korean companies held one-to-one meetings with Mayo Clinic and DMC representatives.

Lee sees this as an opportunity to explore international clinical collaboration rather than simply another overseas business-development meeting.

“The Mayo Clinic/DMC Partnership Day gives us an opportunity to explore international clinical validation and collaboration,” he said in a conversation with KoreaTechToday.

That distinction is important. For a healthcare startup, international validation can become part of the technology itself. Evidence generated with recognized clinical partners can help a company establish credibility with researchers, regulators, pharmaceutical companies and potential customers in other markets.

The data strategy behind Biobytes’ global ambitions

The most consequential part of Biobytes’ strategy may not be its AI technology. It may be the patient data it is building around a specific disease. The company’s M-BANK is designed as a multi-institutional sarcopenia biobank, combining blood, tissue and medical-history data. Biobytes says the project is being built with partner institutions including Wonju Severance Christian Hospital and is intended to reach 3,000 participants by 2027.

That creates a potentially valuable research asset because the company is not collecting a generic health dataset. It is building a cohort around a defined clinical problem. For biomarker research, the value of such a cohort can increase when different forms of information are connected. Clinical histories can be combined with biological samples, functional measurements and other measurements to investigate why patients develop a condition, how the condition progresses and which biological signals might predict disease or treatment response. That is also where the company’s AI strategy intersects with its global ambitions. AI can help analyze complex biological datasets, but the algorithm does not create the underlying clinical evidence. The quality of the resulting insights depends partly on the quality and characterization of the data used to generate them.

For Biobytes, the long-term proposition is therefore potentially broader than AI-based screening. The company describes its business model as spanning AI solutions for hospitals, insurers and health-screening centers, as well as biomarker technology transfer and collaboration with drug-development companies. The international opportunity would be to connect these assets with researchers and pharmaceutical companies that can validate, develop and commercialize them.

Why Asian patient data matters

Lee’s strategy also reflects a wider issue in biomedical research: the uneven representation of populations in global datasets. Asian populations have historically been underrepresented in many large-scale genomic and biomedical datasets. That creates scientific limitations, particularly when research findings are expected to translate across populations with different genetic, environmental and clinical characteristics. For Korean startups, this can create an opportunity. Rather than competing only by reproducing technologies developed elsewhere, companies can contribute datasets generated from Asian populations that help researchers understand diseases and treatment responses more comprehensively. Lee sees this as an important part of Biobytes’ global role.

“I want us to contribute high-quality Asian patient data and build global partnerships for biomarker and drug development,” he said.

The strategic implication is significant. A Korean startup does not necessarily have to become a global healthcare company by establishing operations in every major market. It can become globally relevant by contributing something that international research networks need. In Biobytes’ case, that could mean a combination of Korean clinical expertise, a disease-specific patient cohort, biological samples and AI-based analysis. The challenge is ensuring that these datasets are scientifically rigorous, sufficiently diverse and interoperable with international research environments. Simply having a Korean dataset does not automatically make it globally valuable. The value comes from the quality of the cohort, the depth of its characterization, the ability to validate findings and the extent to which those findings can translate into new diagnostics, biomarkers or therapies.

Korea is building an ecosystem for this kind of globalization

Biobytes’ strategy is unfolding alongside a broader effort to make Korea a stronger platform for global biotech collaboration. The government is developing national bio-data infrastructure and plans to connect data generated through national R&D programs to the National Bio Data Integration Platform. Its AI-bio strategy calls for high-quality biological datasets, AI computing infrastructure and secure environments for using sensitive human-derived data. The government has said it aims to secure more than 7 million bio-data records by 2030, including data covering 1 million Koreans.

The private sector is building complementary infrastructure. In May, CHA Biotech and Thermo Fisher Scientific agreed to establish the K-Bio CIC open-innovation center, designed to support biotech companies from proof of concept through clinical trials, commercialization and global partnering. The planned infrastructure is intended to connect research, clinical development and production while helping domestic biotech companies expand internationally.

Seoul is also using partnerships with global pharmaceutical companies as a route for domestic startup internationalization. In February, the Seoul Metropolitan Government said two Korean bio startups had been selected for global expansion through its Korea AstraZeneca-Seoul BioHub Global Open Innovation Program.

These developments suggest that Korea’s approach to biotech globalization is increasingly moving toward open innovation, where startups, hospitals, pharmaceutical companies, governments and international institutions share parts of the development process. For early-stage companies, that model may be particularly important because they rarely have the resources to build the entire clinical and commercial infrastructure required for global expansion themselves.

There is also a risk in interpreting this trend too optimistically. A conference presentation does not constitute clinical validation. A meeting with Mayo Clinic does not automatically produce a clinical partnership. Selection for an open-innovation program does not guarantee a licensing agreement or drug-development deal. For Biobytes, the difficult work begins after these introductions. The company will need to demonstrate that its research can withstand international scientific scrutiny, that its datasets can produce reproducible findings and that its biomarkers have practical clinical or pharmaceutical value. It will also need to navigate the regulatory and reimbursement environments of different healthcare markets.

This is particularly difficult for digital-health and biotech startups because clinical development operates on a very different timeline from conventional software. The globalization process can therefore be measured less by the number of international meetings a startup attends and more by whether those meetings produce tangible outcomes: clinical studies, research collaborations, licensing agreements, validated biomarkers, pharmaceutical partnerships or products that can enter new markets. That is the test ahead for Biobytes.

A different model for Korean health startups going global

The significance of Biobytes’ strategy extends beyond sarcopenia. Korea has strong capabilities across hospitals, pharmaceuticals, medical technology, digital health and AI. The country is also trying to build international connections that allow these capabilities to move into global markets. But the most successful Korean health startups may not follow a simple path of building a product domestically and exporting it.

A more scalable model could look different. A startup can develop its scientific expertise and proprietary data in Korea, collaborate with domestic hospitals and pharmaceutical companies, validate its technology with international institutions and then use global partnerships to develop products for multiple populations.

That model changes what “going global” means. It is not necessarily about opening a foreign office or finding an overseas distributor. It is about becoming part of the international R&D infrastructure. For Biobytes, the ambition is particularly clear because the company is positioning its data and biomarker research as assets that can connect Korea to global drug-development networks. Lee’s ultimate goal is also broader than commercial expansion.

“Ultimately, our goal is to make early detection and precision treatment of muscle aging accessible even in primary care and underserved communities,” he said.

That objective puts the company’s globalization strategy into a different context. International partnerships are not simply an expansion mechanism. They are intended to help the company improve the evidence, technology and development pathways needed to make its approach useful beyond specialist healthcare settings.

South Korea has spent decades building a powerful industrial base and is now trying to turn that strength into a globally competitive biotechnology ecosystem. The country’s new AI-bio infrastructure, growing pharmaceutical partnerships and international open-innovation programs provide Korean startups with more routes into global healthcare markets. But infrastructure alone will not determine which companies succeed. The more important question is whether startups can convert domestic scientific capabilities into technologies that international researchers, hospitals and pharmaceutical companies consider valuable.

Biobytes’ strategy offers one possible answer. Its path from a Korean sarcopenia-focused healthcare company toward international scientific exposure, pharmaceutical open innovation and clinical collaboration reflects a broader shift from product export to global R&D participation. Its approach also highlights a potential advantage for Korean and Asian health startups: the ability to build high-quality patient datasets that can contribute to a global biomedical ecosystem where Asian populations remain insufficiently represented.

But the real measure of success will come later. ASBMR exposure, InnoBear participation and Mayo Clinic discussions create opportunities. They do not yet establish global market success. The next step is converting those opportunities into evidence, partnerships and products. If Biobytes succeeds in doing that, its story will be about more than taking Korean health technology overseas. It will demonstrate how a Korean startup can use local clinical expertise and Asian patient data as the foundation for international research, biomarker development and precision healthcare. That may ultimately prove to be a more durable path to globalization than simply exporting a Korean product.

Quick Takeaways

• Biobytes is pursuing a partnership-led global strategy, rather than simply exporting its Korean screening technology overseas.
• ASBMR 2026 gives Biobytes international scientific exposure, allowing researchers to assess its sarcopenia research beyond Korea.
• Daewoong Pharmaceutical’s InnoBear program provides a pathway into Korean pharmaceutical open innovation and potential R&D collaboration.
• Mayo Clinic/DMC Partnership Day could support international clinical validation, an important step for a Korean health startup seeking global credibility.
• Asian patient data is central to Biobytes’ strategy. The company wants to contribute high-quality data from Asian populations to global biomarker and drug-development research.
• Biobytes’ M-BANK initiative could become an important research asset, combining clinical information and biological samples around sarcopenia.
• Korea has strong foundations for this model, including advanced hospitals, digital infrastructure, pharmaceutical capabilities and growing government support for AI-bio and national bio-data infrastructure.
• International partnerships are opportunities, not guaranteed outcomes. The real test will be whether they lead to clinical validation, research collaborations, biomarkers, licensing or commercial products.
• Biobytes reflects a broader possible model for Korean startups: build research and data capabilities in Korea, validate internationally, and become part of global R&D networks.
• The bigger shift is from “exporting Korean products” to “connecting Korean innovation with global healthcare.”